|Bid||17.57 x 900|
|Ask||17.58 x 1700|
|Day's Range||17.48 - 18.01|
|52 Week Range||16.81 - 53.96|
|PE Ratio (TTM)||225.00|
|Dividend & Yield||1.10 (6.44%)|
|1y Target Est||N/A|
JERUSALEM/LONDON/FRANKFURT, Aug 16 (Reuters) - Teva Pharmaceutical Industries is looking to team up with other drugmakers to fund some of its development pipeline as it struggles with debts and expiring patents. "We are looking for partners ... a series of partners.
Giving credit where credit is due, I do think Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock looks stronger than it did just a couple of quarters ago. VRX stock has still declined 1.5% so far this year, but the narrative surrounding the company has certainly changed. On the Q2 conference call, Valeant management made a big deal of the fact that 73% of Q2 revenue came from Bausch & Lomb and the Salix business.
Teva Pharmaceutical Industries said on Wednesday it was looking into a series of partnerships to fund some projects in its drug development pipeline, as the drugmaker seeks to pay down more than $5 billion of debt this year.